Assort Health, a patient experience platform powered by specialty-specific agentic AI, has announced the close of a $76 million Series B funding round. The round was led by Lightspeed Venture Partners, with additional investments from Felicis, First Round Capital, Chemistry, A*, Liquid2, and Quiet Capital. This latest funding brings the company’s total to $102 million, following a Series A round just four months earlier.
Assort Health is tackling one of the most frustrating aspects of modern healthcare: the difficulty of scheduling and managing doctor appointments. Patients often face long hold times, disconnected calls, multiple transfers, and repeated requests for the same information. These inefficiencies lead to missed appointments and incomplete care. According to the American Academy of Physician Associates, U.S. adults spend the equivalent of a full workday each month navigating healthcare logistics for themselves and their families.
Assort Health’s platform, Assort OS, has already handled tens of millions of patient interactions across thousands of providers. It goes beyond appointment scheduling to improve every touchpoint in the patient journey, including care navigation, lab testing, prescription renewals, and referrals. The company’s AI agents integrate directly into electronic health record (EHR) and practice management (PM) systems, using natural language processing to streamline communication and resolve inquiries without burdening front office staff.
Healthcare providers are under increasing pressure from reduced reimbursements, rising costs, and staffing shortages. Assort Health offers a technology-driven solution that helps facilities maintain timely and reliable patient access. Its AI agents have reduced patient call wait times by 89% and significantly cut delays in care. The platform supports omnichannel communication and is tailored to the specific needs of each provider, making it a powerful alternative to traditional telemedicine tools.
Assort’s rapid growth is fueled by a culture of execution and a deep commitment to both patient and customer experience. Internal metrics show its engineering team operating at the 100th percentile of velocity, enabling fast iteration and deployment of new features.
With the new funding, Assort Health plans to expand its team and accelerate development of its platform, further enhancing its capabilities and reach. The company is positioning itself as a foundational layer in healthcare operations, aiming to make patient access seamless, efficient, and human-centered.
New board members: As part of the deal, Galym Imanbayev of Lightspeed will join the board, and Paul Ricci, founding CEO of Nuance, will serve as a board advisor.
KEY QUOTES:
“At Assort Health, we are leveraging agentic AI to revolutionize the way provider practices and hospitals engage with patients to remove barriers to care.”
Jon Wang, founder and co-CEO of Assort Health
“Launching our comprehensive platform, Assort OS, we are bringing customers an opportunity to up-level operations and making it easier to get patients in the door.”
Jeffery Liu, founder and co-CEO of Assort Health
“What drew me to Assort Health was the team’s relentless focus on the patient and their dedication to becoming 1% better each day. I am proud to be a part of Assort Health’s journey as they simplify the healthcare experience for patients and providers.”
Apolo Ohno, eight-time Olympic champion and Assort Health investor
“Getting the first impression right during a scheduling call is critical for a good patient experience. Assort’s AI agent easily manages inbound calls and conducts patient outreach as needs change. The new OS platform has also simplified care navigation and internal operations to ensure consistent quality care. Today’s healthcare system is reactive, but with Assort, we can move towards a proactive patient centric system.”
Dr. Titus Abraham, physician at Annapolis Internal Medicine, whose practice handles thousands of inbound calls a month
“Patient engagement is the vital heartbeat of healthcare organizations both clinically and administratively. We are thrilled to back Assort Health as it leads the re-platforming of patient engagement into the AI-native era with superior experience for patients and unprecedented outcomes for the organizations that care for them.”
Galym Imanbayev, MD of Lightspeed Venture Partners, the leader of Assort’s Series B round
